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doi:10.1016/j.jtcvs.2004.04.013472 The Journal of Thoracic and CardioObjective: Biodegradable materials with autologous cell seeding have attracted
much interest as potential cardiovascular grafts. However, pretreatment of these
materials requires a complicated and invasive procedure that carries the risk of
infection. To avoid these problems, we sought to develop a biodegradable graft
material containing collagen microsponge that would permit the regeneration of
autologous vessel tissue. The ability of this material to accelerate in situ cellular-
ization with autologous endothelial and smooth muscle cells was tested with and
without precellularization.
Methods: Poly(lactic-co-glycolic acid) as a biodegradable scaffold was compounded
with collagen microsponge to form a vascular patch material. These poly(lactic-co-
glycolic acid)–collagen patches with (n 10) or without (n 10) autologous vessel
cellularization were used to patch the canine pulmonary artery trunk. Histologic and
biochemical assessments were performed 2 and 6 months after the implantation.
Results: There was no thrombus formation in either group, and the poly(lactic-co-
glycolic acid) scaffold was almost completely absorbed in both groups. Histologic
results showed the formation of an endothelial cell monolayer, a parallel alignment
of smooth muscle cells, and reconstructed vessel wall with elastin and collagen
fibers. The cellular and extracellular components in the patch had increased to levels
similar to those in native tissue at 6 months.
Conclusions: The poly(lactic-co-glycolic acid)–collagen microsponge patch with
and without precellularization showed good histologic findings and durability. This
patch shows promise as a bioengineered material for promoting in situ cellulariza-
tion and the regeneration of autologous tissue in cardiovascular surgery.
In the history of cardiovascular surgery, glutaraldehyde-fixed xenograft,autologous pericardium, polytetrafluoroethylene, and Dacron have beenused as graft material for blood vessel reconstruction or replacement. Thesematerials, however, have well-known limitations, such as thrombogenicity,calcification, shrinkage, and lack of growth potential. The concept of tissueengineering with a biodegradable scaffold was proposed in the 1990s to
overcome these problems.1 This idea has been developed and applied clinically with
autologous cell seeding in recent years.2-6 However, the ex vivo cell-seeding
pretreatment (precellularization) is complicated, invasive, and prone to infection.
Therefore the development of a biodegradable material that allows efficient in situ
cellularization without precellularization is an important strategy. Recently, we
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Ddeveloped a biodegradable patch by compounding a poly-
mer scaffold with collagen microsponge.
Naturally derived collagen has the potential advantage of
interacting with specific cells and is an essential component
of the extracellular matrix that supports endothelial and
smooth muscle cell (SMC) expansion. Moreover, collagen
microsponge is thought to have good cell-attachment prop-
erties because of its porous 3-dimensional structure.7 Con-
sidering these advantages, we proposed the feasibility that a
bioengineered cardiovascular patch with collagen mi-
crosponge might serve as a nonthrombogenic and mechan-
ically durable prosthesis with in situ cellularization.
In the present study we examined the histologic and bio-
chemical characteristics of this patch after its implantation in a
dog model for reconstruction of the right ventricular outflow
Figure 1. The PLGA-collagen microsponge patch was 0
collagen microsponge had a uniformly distributed andtract by using patches with and without a precellularization step.
The Journal of ThoraciMaterials and Methods
Scaffold Design
The patch was fabricated by compounding collagen microsponge
with a biodegradable synthetic polymeric scaffold composed of
fibers made from poly(lactic-co-glycolic acid) (PLGA) 90:10 mesh
(PLGA-collagen patch). The PLGA mesh was provided by Ethi-
con, Inc (Somerville, NJ). The techniques for fabricating the
PLGA-collagen microsponge have been described previously in
detail by Chen and associates.7 Briefly, the PLGA mesh was
immersed in a solution containing type I and type IV collagen (BD
Biosciences; type I:IV  9:1). The collagen-coated mesh was then
frozen at 80°C for 12 hours and lyophilized in a vacuum of 0.2
mm Hg for an additional 24 hours to allow the formation of
collagen microsponge. The collagen microsponge was further
cross-linked by treatment with glutaraldehyde vapor through ex-
posure to a 25% glutaraldehyde aqueous solution at 37°C for 4
thick (a). Scanning electron microscopy showed the
rconnected pore structure (pore size of 50-150 m; b)..6 mm
intehours. The completed patch is shown in Figure 1.
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DCell Isolation, Culture, and Seeding
Segments of the V. saphena magna (3-4 cm) were harvested from
8-month-old beagle dogs. Endothelial cells were obtained by in-
stilling 0.1% collagenase and 0.012% trypsin into the vessel seg-
ments. The resulting endothelial cells were cultured in Dulbecco
modified Eagle medium (Gibco BRL-Life Technologies) supple-
mented with 10% fetal bovine serum (Sigma Chemical Co) and
1% penicillin, streptomycin, and amphotericin (Gibco). To obtain
medial cells, which are mostly SMCs, the remaining de-endothe-
lialized vessel segments were flushed with 0.07% collagenase and
0.03% elastase (Sigma), and the medial cells were cultured with
the same medium. The cell populations were passaged 3 times to
obtain enough cells for cell seeding. For seeding, first 8 million medial
cells were seeded onto the surface of the PLGA-collagen patch (20
15 mm). Twenty-four hours later, 4 million endothelial cells were
dripped onto the seeded patch. After 2 days of dynamic culture with
stirring at 50 rpm in a humidified incubator, which was done to
increase cell-seeding efficiency,8 the patches were implanted.
Ex Vivo Study
Two sets of PLGA-collagen patches (10 10 mm) made with type
I collagen only (n  5) or type I plus type IV mixed collagen (n
 5) were cultured with seeded endothelial cells and SMCs
labeled with a fluorescent cell tracer (PKH26, Sigma) for 3 days.
The attachment and expansion areas of these cells were calculated
with image analysis software (MacScope, Macintosh) and ex-
pressed as the percentage of the visual field.
In Vivo Study
Two sets of PLGA-collagen patches (20  15 mm) prepared with
precellularization (P-C[] group; n  10) or without precellular-
ization (P-C[] group; n  10) were implanted onto the pulmo-
nary trunk of beagle dogs (body weight, approximately 8-10 kg).
Anesthesia was induced with an intravenous bolus infusion of 3
mg/kg ketamine and 3 mg/kg sodium barbiturate and maintained
by means of inhalation of sevoflurane. The heart was approached
through a left anterolateral thoracotomy, entering the chest through
the fourth intercostal space. The pulmonary trunk was partially
clamped and patched with the PLGA-collagen patch by using 5-0
monofilament running sutures. The patch was explanted 2 (n  5
in each group) or 6 (n  5 in each group) months after the
implantation. All animals received humane care in compliance
with the “Guide for the Care and Use of Laboratory Animals”
published by the National Institutes of Health.
Histologic and Immunohistologic Examination
Explanted tissue specimens were examined with hematoxylin-
eosin–, elastica van Gieson–, and von Kossa–stained paraffin or
immunostained frozen sections. The antibodies used for immuno-
histochemistry were monoclonal antibodies to CD31 (clone JC/
70A, DAKO) and -smooth muscle actin (clone HHF35, DAKO),
and a polyclonal antibody to von Willebrand factor (factor VIII–
related antigen; rabbit, N1505, DAKO). Other antibodies used for
immunofluorescence were a monoclonal antibody to collagen type
I (clone COL-1, Sigma), and a polyclonal antibody to collagen
type IV (rabbit, Rockland).
474 The Journal of Thoracic and Cardiovascular Surgery ● SeptMechanical Strength
The maximal tensile strength of the PLGA-collagen patch was
measured before implantation and 2 and 6 months after implanta-
tion with a TENSILON mechanical tester (Orientec Co, Ltd). The
dimensions of the patches used for the tensile test were 5  20
mm, and the patches were pulled to failure at a rate of 10 mm/min.
The tension strength was represented by N units (1 N  1 MPa ·
measured mm2).
Biochemical Examination
A 4-hydroxyproline assay was used to measure the collagen con-
tent in the explanted patch. The elastin content was quantified by
determining the dry weight of the insoluble material after delipi-
dation in acetone–diethyl ether and solubilization in 0.1 N NaOH
at 98°C. The DNA content, which reflects the cellular component,
was measured with a Hoechst dye assay (Hoechst 33258, Molec-
ular Probes Inc). The amounts of these cellular and extracellular
components in the constructs were compared with those of the
native pulmonary artery from the same animal and were expressed
as a percentage of the native level.
All results were expressed as the mean value  SD.
Results
Ex Vivo Study
The attachment and expansion area of endothelial cells
cultured on the PLGA-collagen type I plus IV (55% 11%)
was higher than on the PLGA-collagen type I (40%  6%).
The attachment and expansion area of SMCs on the PLGA-
collagen type I plus IV (69%  10%) was also higher than
on the PLGA-collagen type I (40%  6%).
In Vivo Study
Macroscopic findings. On macroscopic inspection, nei-
ther group showed thrombus formation on the internal sur-
face of the patch. The size of the patches was unchanged 6
months after implantation (before implantation, 20  15
mm; P-C[], 20.4  2.8  14.2  0.8 mm; P-C[], 19.5
 1.3  14.3  1.3 mm). There was no intimal thickening
after the implantation of patches either with or without
precellularization. The thickness of the precellularized
patch, untreated patch, and native pulmonary artery were
1.1  0.1, 1.0  0.1, and 1.0  0.1 mm, respectively
(Figure 2).
Histologic examination. Microscopic examination of
the patch with precellularization 2 months after implanta-
tion showed that numerous seeding cells, which were la-
beled with a fluorescent tracer, remained on the patch (Fig-
ure 3). Hematoxylin-eosin staining showed almost complete
absorption of the PLGA polymer in both groups 2 months
after implantation (Figure 4, a). A monolayer of endothelial
cells covering the surface of the patch was confirmed by
staining with factor VIII and CD31 (Figure 4, b). -Smooth
muscle actin staining showed a parallel alignment of SMCs
in the wall of the patch in both groups (Figure 4, c). Elastica
van Gieson staining demonstrated the remodeling of elastin
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Dfibers in the tissue (Figure 4, d). Immunofluorescence stain-
ing of collagen showed a similar pattern as that seen in
native tissue, with type IV collagen present at the basal
membrane (Figure 5). These histologic findings were almost
the same in both the grafts with and those without precel-
lularization. No calcification was detected by means of von
Kossa staining, and the architecture of the implanted patch
was similar to that of the native pulmonary artery wall 6
months after implantation (Figure 6).
Mechanical strength. The mechanical tensile strength
of the PLGA-collagen patch before and after implantation
was greater than that of the native pulmonary artery (before
implantation: 74.8 3.2 N; after 2 months: P-C[], 14.8
2.6 N; P-C[], 14.2  4.4 N; after 6 months: P-C[], 26.8
 7.0 N; P-C[], 28.7  8.1 N; native pulmonary artery:
2.7  0.9 N).
Biochemical examination. The 4-hydroxyproline assay
demonstrated that the implanted patch had almost the same
collagen content as the native tissue (after 2 months:
Figure 2. Macroscopic findings 6 months after implan
arrows show the border of the patch and the native pul
was not significantly different from that of the native
Figure 3. Microscopic findings of the patch with p
numerous remaining seeding cells, which were labeleP-C[], 127%  26%; P-C[], 110%  15%; after 6
The Journal of Thoracimonths: P-C[], 135%  35%; P-C[], 117%  30% of
the collagen content of native pulmonary artery). The elastin
content was about 60% that of native tissue at 2 months and
increased to a level similar to that of native tissue at 6
months (after 2 months: P-C[], 51%  42%; P-C[],
54% 29%; after 6 months: P-C[], 91% 18%; P-C[],
90% 31%). The DNA assay revealed an increase in DNA
in the patches to levels comparable with that of native
pulmonary artery at 2 months after implantation (after 2
months: P-C[], 113%  23%; P-C[], 95%  22%; after
6 months: P-C[], 101%  25%; P-C[], 87%  26%).
Discussion
In this study we evaluated the histologic, mechanical, and
biochemical characteristics of the PLGA-collagen mi-
crosponge patch with or without precellularization after its
implantation into a dog pulmonary artery. PLGA is usually
absorbed at 2 months in situ.9 In agreement with this, all
cases in the present study showed the disappearance of the
. There was no thrombus formation in any case. The
ry artery. The appearance of the reconstructed portion
onary artery.
lularization after 2 months of implantation showed
th a fluorescent tracer. (Original magnification 40 .)tation
monarecelpolymeric fiber at 2 months. The histologic findings at 2
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Dmonths after grafting showed good cellularization in both
groups. The implanted patches in both groups had sufficient
mechanical strength for reconstruction of the vascular wall,
Figure 4. Histologic findings 2 months after implant
staining (H-E) with (a-1) and without (a-2) precellulariz
precellularization, -smooth muscle actin staining (A
elastica van Gieson staining (EVG) with (d-1) and with
the formation of an endothelial cell monolayer, a paral
elastin and collagen fibers in both groups.possibly because of the addition of fibrous connective tissue
476 The Journal of Thoracic and Cardiovascular Surgery ● Septresulting from the wound-healing process. We used tensile
strength as our biomechanical test, which might not com-
pletely reflect the physiologic biomechanical properties of
. (Original magnification 100 .) Hematoxylin-eosin
treatment, CD31 staining with (b-1) and without (b-2)
) with (c-1) and without (c-2) precellularization, and
d-2) precellularization are shown. These results show
ignment of SMCs, and reconstructed vessel wall withation
ation
-SMA
out (
lel althe patch. Nonetheless, the tensile strength at 2 months of
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Dimplantation, when the polymer had been absorbed, was
comparable with that of native pulmonary artery. There was
no sign of rupture in any case up to 6 months after implan-
tation. The percentage of cellular and extracellular compo-
nents in the patch had increased to levels similar to those in
Figure 5. Immunofluorescence staining of collagen. (O
and red shows type IV collagen. The patch 2 months
similar pattern as that seen in the native pulmonary a
Figure 6. Hematoxylin-eosin staining (original magnifi
(a-1) and without (a-2) precellularization showed a sim
muscle actin staining (original magnification 40 ) of t
(b-2) precellularization showed widely expanded SMCnative tissue at 6 months. In our experiments quantifying the
The Journal of Thoracicollagen content, we could not discriminate between the
bovine collagen of the initial patch and the newly generated
canine collagen. However, immunofluorescence staining of
the collagen showed a pattern similar to that of native tissue,
such as the wave form of type I collagen and the presence
l magnification 100 .) Green reveals type I collagen,
implantation without precellularization (a) showed a
(b), with type IV collagen at the basal membrane.
n 40 ) of the patch 6 months after implantation with
architecture to the native pulmonary artery. -Smooth
tch 6 months after implantation with (b-1) and without
the wall of the patch.rigina
aftercatio
ilar
he paof type IV collagen at the basal membrane.
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heart surgery have been found to be unsatisfactory when
evaluated with respect to long-term results. Furthermore,
they are associated with serious problems, such as calcifi-
cation, peel formation, and a lack of growth potential.10,11
The concept of tissue engineering with a biodegradable
scaffold has been proposed1 and tested2-6 both in experi-
mental and clinical situations to overcome these limitations.
In previous reports precellularization with autologous cells
harvested from the bone marrow, peripheral vessels, or
blood was performed before implantation of the grafts. The
harvesting and seeding of the cells, however, have the
potential to cause complications, such as hemodynamic
effects caused by bone marrow aspiration and contamina-
tion during the cell culture and seeding steps before implan-
tation.
On the other hand, the collagen microsponges we used in
the present study have a porous 3-dimensional structure
(pore sizes of 50-150 m) that accelerates the cell attach-
ment to the scaffold.7 The hydrophilicity of the collagen and
interconnected pore structure of the microsponge facilitate
the attachment and spreading of cells throughout the
patch.12 In a preliminary experiment we found that the
PLGA scaffold without the collagen microsponge gave rise
to immature cellularization and thrombus formation (data
not shown). Another report similarly shows that pulmonary
artery replacement with a polymer tube without precellular-
ization resulted in severe thrombus formation that led to
pulmonary stenosis.13 Here we did not study endotheliali-
zation earlier than 2 months after implantation. However,
the collagen microsponge coating on the polymer scaffold
might have a role in preventing the thrombus formation
associated with early endothelialization. In the present study
there was no thrombus formation on the surface of the
patch, even without precellularization. This means that coat-
ing the PLGA material with collagen microsponge might
have a similar effect as preseeding the PLGA at phases
earlier than 2 months.
In addition to precellularization, many strategies have
been used to promote cell differentiation on graft materials,
such as the application of other extracellular matrix com-
ponents or growth factors.14-17 In this study we evaluated
using 2 types of collagen, type I and type IV, as an additive
for regeneration of the vascular vessel wall. Collagen type
IV, which localizes to the basement membranes of vascular
tissue, has an important role in cell differentiation.18 Our
findings with ex vivo experiments suggested that adding
type IV collagen to the graft would be more effective than
using type I collagen alone for promoting regeneration in
situ. The use of a type I and type IV mixed collagen
microsponge might promote cellularization and differentia-
tion, making the procedure easier.
478 The Journal of Thoracic and Cardiovascular Surgery ● SeptPrevious studies demonstrated the existence of circulat-
ing endothelial and smooth muscle progenitor cells, which
contribute to vasculogenesis and angiogenesis.19-21 Re-
cently, it was shown that adult bone marrow cells can
differentiate into vascular endothelial cells and SMCs. Han
and associates22 found that bone marrow cells contribute to
the formation of neointimal lesions in the injured vessels of
mice. Shimizu and associates23 and Sata and coworkers24
demonstrated that -actin–positive cells in the neointimal
lesions of allografts were colocalized with -galactosidase
positively stained cells in a chimeric mouse expressing
-galactosidase in its bone marrow cells. Therefore the ideal
condition for vascular reconstruction would involve a
PLGA-collagen patch to which circulating progenitor cells
would migrate and which would support their survival in
situ. The concept of regeneration with the PLGA-collagen
patch without precellularization is based on the idea of
supplying an in situ bioreactor and incubator for vascular
progenitor cells. In further investigation, we have to evalu-
ate the differences in the cellular ingrowth caused by the
species differences and operative age.
Regarding the biodegradable scaffold, as previously re-
ported,25,26 the choice of biodegradable polymer is impor-
tant. Several factors, such as degradation time, biocompat-
ibility, and ease of handling for surgical intervention should
be improved to make a new material preferable to a con-
ventional one. Considering these factors, in this study we
selected the PLGA mesh, which is already used as a surgical
material and has a structure that is suitable for compounding
with collagen microsponge. As we move toward the appli-
cation of this patch to the systemic circulation, we are
currently attempting to improve the scaffold design by
reinforcing the outside with a woven poly-L-lactide fabric.
The major limitations of this study are the small number
and short durations of the observations. The size of the
implanted patch was also relatively small. Therefore the
long-term findings regarding the efficacy of this material
without precellularization might not be the same for a large
conduit implanted into the right ventricular outflow tract or
if another model is used. However, we believe that our
strategy without precellularization might be a useful option
for a novel tissue-engineering technique. The use of a xe-
nogenous substance, such as collagen, might be a limitation,
although prosthetic vascular grafts coated with collagen are
already widely used in clinical situations. Moreover, for the
clinical use of this graft in the repair of congenital heart
disease, its durability and potential for growth should be
evaluated over a long-term follow-up period. Nevertheless,
this study is valuable as the first report of a newly developed
bioengineered material that is feasible for grafting in car-
diovascular surgery. Further investigation will be directed
toward evaluating its potential for clinical applications.
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In the present study the PLGA-collagen microsponge patch
showed good in situ cellularization and synthesis of extra-
cellular matrix in a dog model for reconstruction of the
pulmonary artery. The PLGA-collagen patch has promise as
a bioengineered material for the reconstruction of autolo-
gous tissue in cardiovascular surgery.
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